In the second 6 months of the study, people who kept taking tesamorelin reduced their visceral fat by nearly 18%, while those who stopped regained the fat quickly, showing a clear cause-and-effect relationship.

Administration of tesamorelin results in a statistically significant reduction in visceral adipose tissue volume compared to placebo, with a mean reduction of approximately 11% after 6 months of treatment.

In a 6-month randomized, placebo-controlled trial, tesamorelin significantly reduced both visceral and hepatic (liver) fat, with liver fat reduction being particularly important as it improves insulin sensitivity and glucose metabolism.

A daily injection called tesamorelin helps HIV patients on medication lose belly fat inside their abdomen, while a fake shot doesn’t.

If HIV patients keep taking tesamorelin for a full year, their dangerous belly fat drops by about 18% compared to when they started — but we don’t know how much better that is than just stopping the drug, because the placebo group didn’t stay on it for a year.

Tesamorelin independently increases fat density in visceral and subcutaneous adipose tissue, indicating improved fat quality with smaller adipocytes, better vascularization, reduced hypoxia, and decreased inflammation, independent of fat quantity changes.